Your session is about to expire
← Back to Search
Other
BB3 for Delayed Graft Function
Phase 2
Waitlist Available
Research Sponsored by Angion Biomedica Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
Summary
The objective of the study is to evaluate the safety and activity of a investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury and are at risk for dialysis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Urine production
Secondary study objectives
Biomarkers
Change from baseline urine production
Daily urine output
+7 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: BB3Active Control1 Intervention
Group II: Normal SalinePlacebo Group1 Intervention
Placebo
Find a Location
Who is running the clinical trial?
Angion Biomedica CorpLead Sponsor
11 Previous Clinical Trials
932 Total Patients Enrolled
2 Trials studying Delayed Graft Function
265 Patients Enrolled for Delayed Graft Function
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,410 Previous Clinical Trials
4,324,861 Total Patients Enrolled
2 Trials studying Delayed Graft Function
1,691 Patients Enrolled for Delayed Graft Function
Weizhong Cai, PhDStudy DirectorSponsor GmbH
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger